Bayforest Capital’s Ascendis Pharma A/S ASND Stock Holding History

Bayforest Capital’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-198	Closed	-$45.3K	–	958
2026 Q1	$45.3K	Buy	+198	New	+$44.4K	0.05%	585
2025 Q3	–	Sell	-51	Closed	-$8.8K	–	731
2025 Q2	$8.8K	Buy	+51	New	+$8.31K	﹤0.01%	638
2025 Q1	–	Sell	-1,165	Closed	-$160K	–	728
2024 Q4	$160K	Buy	+1,165	New	+$153K	0.2%	182

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Bayforest Capital's ASND Position: Q2 2026 in Review

Bayforest Capital sold out of Ascendis Pharma A/S (ASND) in Q2 2026, closing a stake of 198 shares — an estimated $45.3K sold.

Bayforest Capital first reported a position in ASND in Q4 2024 and held it in 3 quarters. The position peaked at $160K in Q4 2024. 312 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

Bayforest Capital reported no remaining Ascendis Pharma A/S position as of Q2 2026 after selling out during the quarter.
Bayforest Capital sold 198 Ascendis Pharma A/S shares in Q2 2026, an estimated $45.3K.
Bayforest Capital first reported a position in Ascendis Pharma A/S in Q4 2024 and held it in 3 quarters.
Bayforest Capital's Ascendis Pharma A/S position peaked at $160K in Q4 2024.
312 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on Bayforest Capital's 13F filing for Q2 2026, filed 5 Aug 2026.